Answer
The press release you provided about Scholar Rock’s second‑quarter 2025 results does not contain any information on the company’s cash balance, cash‑burn rate, or projected cash runway. Consequently, a direct comparison of Scholar Rock’s cash runway to that of other companies developing SMA (spinal muscular atrophy) therapies cannot be made from this news release alone.
What you would need to assess the runway comparison
| Metric | Where it’s typically disclosed | How it’s used for comparison |
|---|---|---|
| Cash and cash equivalents | Balance‑sheet line item in quarterly or annual 10‑Q/10‑K filings | Shows the total amount of liquid resources available. |
| Net cash‑burn per quarter | Calculated from operating cash outflows in the cash‑flow statement or disclosed in earnings releases. | Determines how many quarters of cash the company has left at current spending levels. |
| Projected cash‑runway (quarters/years) | Often provided as a management commentary in earnings releases, investor presentations, or 8‑K filings. | Directly compares how long a company can fund operations without raising additional capital. |
| Capital‑raising plans (e.g., upcoming equity offerings, debt facilities) | Mentioned in press releases, SEC filings, or conference call transcripts. | Impacts the effective runway by adding future cash inflows. |
How to obtain the needed data
- SEC filings – Review Scholar Rock’s most recent Form 10‑Q (for Q2 2025) or Form 8‑K press release. The “Liquidity and Capital Resources” section will usually state the cash balance and the company’s estimate of how many quarters of cash it has remaining.
- Investor presentations – Companies often include a cash‑runway slide in slide decks presented at analyst calls or conferences.
- Analyst research – Equity research reports on the SMA therapeutic space frequently summarize each peer’s cash position and runway, enabling side‑by‑side comparisons.
Typical peer context (general, not specific to Scholar Rock)
- Biogen (BIIB) – Holds a multi‑billion‑dollar cash position with a runway extending well beyond the next 5 years, supported by its established SMA product (Spinraza) and a robust cash‑generation profile.
- Novartis (NVS) – Gene‑therapy unit (e.g., Zolgensma) – Large cash reserves and a long runway, reflecting its scale and diversified portfolio.
- Smaller, pre‑approval SMA developers (e.g., GeneTx, Avidity) – Often report cash runways of 12–24 months, requiring additional financing before pivotal regulatory milestones.
Bottom line
Based solely on the information in the August 6, 2025 Business Wire release, we cannot determine Scholar Rock’s cash runway or how it stacks up against other SMA‑focused peers. To answer the question accurately, you’ll need to locate Scholar Rock’s cash‑balance and runway disclosures (typically found in its SEC filings or detailed investor presentations) and then compare those figures to the publicly disclosed cash positions of the other SMA‑therapy companies.